

CLEARBRIDGE AGGRESSIVE GROWTH FUND

Investment overview

Invests in companies across capitalizations with high growth potential

Patient management seeks capital appreciation from a high-conviction, low-turnover portfolio of companies with new or disruptive technologies, products and services

Bottom-up stock selection favors strong fundamentals, committed management and a clear market advantage

Average annual total returns & fund expenses^A (%) as of Mar. 31, 2022

	Without sales charges					With maximum sales charges					Expenses		Inception date
	1-Yr	3-Yr	5-Yr	10-Yr	Inception	1-Yr	3-Yr	5-Yr	10-Yr	Inception	Gross	Net	
Class A	-6.89	9.64	7.22	10.30	11.31	-12.25	7.50	5.96	9.65	11.13	1.11	1.11	10/24/83
Class C	-7.54	8.87	6.48	9.54	10.24	-8.17	8.87	6.48	9.54	10.24	1.84	1.84	05/13/93
Class FI	-6.98	9.61	7.20	10.28	7.30	-6.98	9.61	7.20	10.28	7.30	1.15	1.15	04/30/07
Class I	-6.62	9.98	7.56	10.65	10.32	-6.62	9.98	7.56	10.65	10.32	0.82	0.82	01/30/96
Class IS	-6.53	10.07	7.64	10.76	9.99	-6.53	10.07	7.64	10.76	9.99	0.74	0.74	08/04/08
Class R	-7.23	9.29	6.89	9.98	7.10	-7.23	9.29	6.89	9.98	7.10	1.44	1.44	12/28/06
Benchmark	12.86	22.68	20.16	16.64	—	12.86	22.68	20.16	16.64	—			

Cumulative total returns (%) as of Mar. 31, 2022 (without sales charges)

	3 Mo	YTD	2021	2020	2019	2018	2017	2016	2015	2014	2013
Class A	-8.71	-8.71	7.85	19.47	24.17	-7.97	14.28	5.71	-4.40	14.55	44.62
Class C	-8.87	-8.87	7.09	18.65	23.30	-8.58	13.48	4.97	-5.07	13.74	43.67
Class FI	-8.74	-8.74	7.78	19.45	24.19	-7.95	14.28	5.71	-4.42	14.60	44.52
Class I	-8.64	-8.64	8.17	19.86	24.57	-7.67	14.64	6.03	-4.12	14.91	45.12
Class IS	-8.63	-8.63	8.27	19.94	24.66	-7.60	14.74	6.17	-4.00	15.03	45.30
Class R	-8.78	-8.78	7.46	19.12	23.80	-8.24	13.94	5.40	-4.68	14.24	44.32
Benchmark	-9.25	-9.25	25.85	38.26	35.85	-2.12	29.59	7.39	5.09	12.44	34.23

Performance shown represents past performance and is no guarantee of future results. Current performance may be higher or lower than the performance shown. Investment return and principal value will fluctuate so shares, when redeemed, may be worth more or less than the original cost. Class A shares have a maximum front-end sales charge of 5.75%. Class C shares have a one-year CDSC of 1.0%. If sales charges were included, performance shown would be lower. Total returns assume the reinvestment of all distributions at net asset value and the deduction of all Fund expenses. Total return figures are based on the NAV per share applied to shareholder subscriptions and redemptions, which may differ from the NAV per share disclosed in Fund shareholder reports. Performance would have been lower if fees had not been waived in various periods. YTD is calculated from January 1 of the reporting year. All classes of shares may not be available to all investors or through all distribution channels. For the most recent month-end information, please visit www.franklintempleton.com.

Effective August 2, 2021, except as noted below, Class C (including Class C, Class C-1 & Class C-2) shares will automatically convert to Class A shares after the shares have been held for 8 years from their original purchase date. The initial conversion took place on August 16, 2021. Refer to the fund's prospectus or contact your Service Agent for more information.

Sector allocation (%) as of Mar. 31, 2022

	Fund	Benchmark		Fund	Benchmark
Information Technology	35.4	44.8	Financials	1.8	2.6
Health Care	26.1	9.8	Materials	1.6	1.1
Communication Services	25.9	10.0	Consumer Discretionary	1.6	18.2
Industrials	7.6	6.7			

Growth of \$10,000

Class A shares – Inception through Mar. 31, 2022
Excluding the effects of sales charges



Share class codes

	Symbol	CUSIP		Symbol	CUSIP
A	SHRAX	52468C109	I	SAGYX	52468C406
C	SAGCX	52468C307	IS	LSIFX	52468C703
FI	LMPFX	52468C604	R	LMPRX	52468C505

Benchmark (BM)

Russell 3000 Growth Index (USD)

Fund facts as of Mar. 31, 2022

Dividend frequency, if any	Annual
Morningstar category	Large Blend
Lipper category	Multi-Cap Core Funds
Turnover (fiscal yr)	8%

^AGross expenses are the Fund's total annual operating expenses for the share class(es) shown. Net expenses for Class(es) A, C, FI, I, IS & R reflect contractual fee waivers and/or reimbursements, where these reductions reduce the Fund's gross expenses, which cannot be terminated prior to Dec 31, 2023 without Board consent.

Any information, statement or opinion set forth herein is general in nature, is not directed to or based on the financial situation or needs of any particular investor, and does not constitute, and should not be construed as, investment advice, forecast of future events, a guarantee of future results, or a recommendation with respect to any particular security or investment strategy or type of retirement account. Investors seeking financial advice regarding the appropriateness of investing in any securities or investment strategies should consult their financial professional.

CLEARBRIDGE AGGRESSIVE GROWTH FUND

Top 10 holdings (%) as of Mar. 31, 2022

Broadcom Inc	7.4
Vertex Pharmaceuticals Inc	7.0
UnitedHealth Group Inc	6.9
Comcast Corp	6.4
TE Connectivity Ltd	5.9
Wolfspeed Inc	5.0
Autodesk Inc	4.0
Twitter Inc	3.9
L3Harris Technologies Inc	3.4
CrowdStrike Holdings Inc	3.1

Statistics as of Mar. 31, 2022

	Fund	Benchmark
Net assets	\$5.7B	–
Number of holdings	45	1743
Weighted average cap	\$103.5B	\$897.4B
Weighted median cap	\$42.7B	\$268.1B

Portfolio management

Evan Bauman (industry since 1996) and Aram Green (industry since 2001) co-manage your Fund. ClearBridge Investments offers institutional and individual investors a variety of traditional and alternative equity strategies. With an investment heritage dating back over 60 years, ClearBridge offers distinctive manager insights and proprietary fundamental research.

What should I know before investing?

Equity securities are subject to price fluctuation and possible loss of principal. Small- and mid-cap stocks involve greater risks and volatility than large-cap stocks. International investments are subject to special risks, including currency fluctuations and social, economic and political uncertainties, which could increase volatility. The Fund may be significantly overweight to underweight certain companies, industries or market sectors, which may cause the Fund's performance to be more sensitive to developments affecting those companies, industries or sectors. Short selling is a speculative strategy. Unlike the possible loss on a security that is purchased, there is no limit on the amount of loss on an appreciating security that is sold short.

Where can I find more information?

You'll find the most current performance data, commentary, prospectus and more information on each of our managers and products at www.franklintempleton.com.

Risk statistics as of Mar. 31, 2022

Measures based on Class A. Benchmark = Russell 3000 Growth Index (USD).

	1-Yr		3-Yr		5-Yr		10-Yr	
	Fund	Benchmark	Fund	Benchmark	Fund	Benchmark	Fund	Benchmark
Beta	0.68	1.00	0.87	1.00	0.90	1.00	0.95	1.00
R-squared	0.76	1.00	0.73	1.00	0.76	1.00	0.76	1.00
Sharpe ratio	-0.44	0.75	0.52	1.11	0.41	1.08	0.67	1.10
Standard deviation (%)	14.07	18.12	19.87	19.54	18.16	17.51	15.73	14.52
Alpha	-14.39	0.00	-8.15	0.00	-9.15	0.00	-4.50	0.00
Information ratio	-2.17	–	-1.22	–	-1.42	–	-0.82	–
Tracking error	9.11	0.00	10.64	0.00	9.10	0.00	7.75	0.00

Beta measures the sensitivity of an investment to the movement of its benchmark. A beta higher than 1.0 indicates the investment has been more volatile than the benchmark and a beta of less than 1.0 indicates that the investment has been less volatile than the benchmark. **R-squared** measures the strength of the linear relationship between the Fund and its benchmark. R Squared at 1 implies perfect linear relationship and zero implies no relationship exists. **Sharpe ratio** is a risk-adjusted measure, calculated using standard deviation and excess return to determine reward per unit of risk. The higher the sharpe ratio, the better the fund's historical risk-adjusted performance. **Standard deviation** measures the risk or volatility of an investment's return over a particular time period; the greater the number, the greater the risk. **Alpha** measures performance vs. a benchmark on a risk-adjusted basis. A positive alpha of 1.0 means the portfolio has outperformed its benchmark index by 1%. Correspondingly, a similar negative alpha would indicate an underperformance of 1%. **Tracking Error** is the dispersal of differences between the returns obtained by the Fund and the benchmark variation. **Information Ratio** is the ratio of annualized expected residual return to residual risk. **Turnover** is a measure of the Fund's trading activity which represents the portion of the Fund's holdings that has changed over a year. There is no assurance that the Fund will maintain its current level of turnover.

The **Russell 3000 Growth Index** measures the performance of those Russell 3000 Index companies with higher price-to-book ratios and higher forecasted growth values. Investors cannot invest directly in an index and unmanaged index returns do not reflect any fees, expenses or sales charges.

Active share is a measure of the percentage of stock holdings in a manager's portfolio that differs from the benchmark index.

©2022 Franklin Distributors, LLC. Member FINRA/SIPC. ClearBridge Investments, LLC, and Franklin Distributors, LLC, are Franklin Templeton affiliated companies.

Before investing, carefully consider a Fund's investment objectives, risks, charges and expenses. You can find this and other information in each prospectus, or summary prospectus, if available, which is available at www.franklintempleton.com. Please read it carefully.



FRANKLIN
TEMPLETON